Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors

Summary

Aim of the FavorAx study is to evaluate preliminary efficacy and safety of Axitinib in metastatic renal cell carcinoma patients with favorable IMDC prognostic factors who had progressed on sunitinib or pazopanib in the first-line setting.

Timeline

Start

2016-01

Primary completion

2018-06

Completion

2018-08

Drugs

Indications